Allokid, allopurinol 100 mg, powder for solution for injection
Orphan Drug Designation EU/3/15/1493
Allopurinol 100 mg
Treatment of perinatal asphyxia
Allopurinol 100 mg is intended for the treatment of perinatal asphyxia. Allopurinol is administered per i.v.-injection to the youngest children (immediately after birth). The significance is high: to prevent or at least limit brain damage from lack of oxygen during delivery of the baby.
ACE participates in the ALBINO-trial, an ambitious “Horizon 2020”-project. Horizon 2020 is the biggest EU research and innovation funding programme.
In the ALBINO-trial, children with asphyxia are treated with Allokid in addition to so called hypothermia –treatment (golden standard) following birth.
ACE Pharmaceuticals has received an Orphan Drug Designation (EU/3/15/1493) for Allopurinol 100 mg from the European Medicines Agency (EMA) in May 2015.
Allokid is not licensed in any country.
Allokid is not yet available.